Colombia to enforce declaration of public interest for Glivec

Home/Policies & Legislation | Posted 28/10/2016 post-comment0 Post your comment

Colombia’s Ministry of Health and Social Protection (MinSalud) confirmed on 14 September 2016 that it was to enforce a declaration of public interest and cut the prices for blockbuster cancer drug Glivec (imatinib) by 45%.

Imatinib V13D12

The move has prompted industry organizations, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the National Association of Manufacturers (NAM) to condemn the move. PhRMA has expressed disappointment, saying that there are ‘no legitimate reasons’ for the move. While NAM believes the move is ‘unwarranted, but also undermines [Colombia’s] own economic growth trajectory’. PhRMA adds that ‘the enforcement of a declaration of public interest as a mechanism to impose superfluous price controls sets a harmful global precedent, undermining the incentives that enable high-risk research and development investments in life-saving medical innovation and a host of other cutting-edge industries.’

The move by Colombia’s MinSalud follows the recommendation by a committee of the Colombian Ministry of Health and Social Protection that a compulsory license be issued for Glivec [1]. The country later appealed to the World Health Organization (WHO) and received a sympathetic reception. On 23 May 2016 at the WHO Assembly in Geneva Colombia’s Minister of Health Alejandro Gaviria said that the sustainable development of countries like Colombia was being threatened by the high prices of necessary drugs [2].

PhRMA, however, insists that ‘the way to achieve access to medicines is not through compromising incentives for innovation but by leveraging the collective abilities, strengths and resources of all stakeholders to improve health outcomes’.

Related articles
Call for compulsory license for biosimilar trastuzumab emtansine

India may move away from compulsory licensing

1. GaBI Online - Generics and Biosimilars Initiative. Colombia recommends compulsory licence for Glivec []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Oct 28]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Colombia fighting to break Glivec monopoly []. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Oct 28]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: MinSalud, NAM, PhRMA, RCNRadio

comment icon Comments (0)
Post your comment
Related content
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
MERCOSUR: new tariff for biological and biosimilar without Latin equity
138 AA011155
Home/Policies & Legislation Posted 03/09/2021
New trade agreement between Mexico, the US and Canada
62 MD001919
Home/Policies & Legislation Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010